Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic
December 12, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the...
Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results
November 13, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its...
Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement
October 28, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has...
Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences
October 14, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its...
Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma
October 08, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial...
Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials
September 24, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the...
Salarius Pharmaceuticals Announces Senior Leadership Changes
September 13, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment...
Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month
September 12, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for...
Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma
August 26, 2019 07:00 ET
|
Salarius Pharmaceuticals
PHOENIX and HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a...
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
August 12, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief...